MDDM - New Ingredient in Ecstasy Tablets

B. Byrska, K. Masier, R. Stanaszek
{"title":"MDDM - New Ingredient in Ecstasy Tablets","authors":"B. Byrska,&nbsp;K. Masier,&nbsp;R. Stanaszek","doi":"10.1016/j.etdah.2023.100075","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>In 2020, the first Ecstasy tablets were sent to our Institute, in which, in addition to MDMA and MDA, new psychoactive substance - MDDM (3,4-methylenedioxydimethylamphetamine) were also detected.</div></div><div><h3>Methods</h3><div>The research material consisted of 150 tablets seized in five cases from two cities in Poland between 2020-2022. The qualitative analysis of the tablets was carried out by GC-MS. Quantitative analysis was performed by UHPLC-PDA.</div></div><div><h3>Results</h3><div>The main ingredient of the tested Ecstasy tablets was MDA. The second most abundant ingredient was MDDM and MDMA was at the lowest purity. All the tablets were shaped like “the head of a star wars stormtrooper” and in off-white colour. The mass of tablets was in range 0.32-0.36 g. The content of psychoactive substances in one tablet was in range: 38-74 mg MDA, 12-28 mg MDDM, and 3-9 mg MDMA.</div></div><div><h3>Conclusions</h3><div>In the last three years new ingredient - MDDM was introduced to Ecstasy tablets. MDDM produces mild psychoactive effects that are not well characterized. It is a new psychoactive substance, and very little data exists about its pharmacological properties, metabolism, toxicity and dosage. Due to possible interactions between MDDM, MDA and MDMA, taking tablets containing such mixtures can lead to accidental overdose and dangerous synergistic effects.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"4 ","pages":"Article 100075"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging trends in drugs, addictions, and health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667118223000260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

In 2020, the first Ecstasy tablets were sent to our Institute, in which, in addition to MDMA and MDA, new psychoactive substance - MDDM (3,4-methylenedioxydimethylamphetamine) were also detected.

Methods

The research material consisted of 150 tablets seized in five cases from two cities in Poland between 2020-2022. The qualitative analysis of the tablets was carried out by GC-MS. Quantitative analysis was performed by UHPLC-PDA.

Results

The main ingredient of the tested Ecstasy tablets was MDA. The second most abundant ingredient was MDDM and MDMA was at the lowest purity. All the tablets were shaped like “the head of a star wars stormtrooper” and in off-white colour. The mass of tablets was in range 0.32-0.36 g. The content of psychoactive substances in one tablet was in range: 38-74 mg MDA, 12-28 mg MDDM, and 3-9 mg MDMA.

Conclusions

In the last three years new ingredient - MDDM was introduced to Ecstasy tablets. MDDM produces mild psychoactive effects that are not well characterized. It is a new psychoactive substance, and very little data exists about its pharmacological properties, metabolism, toxicity and dosage. Due to possible interactions between MDDM, MDA and MDMA, taking tablets containing such mixtures can lead to accidental overdose and dangerous synergistic effects.
摇头丸片中的新成分MDDM
2020年,我院收到第一批摇头丸片,除MDMA、MDA外,还检出新型精神活性物质MDDM(3,4-亚甲基二氧二甲基安非他明)。方法研究材料包括2020-2022年在波兰两个城市的5起案件中缴获的150片。采用气相色谱-质谱法对片剂进行定性分析。采用UHPLC-PDA进行定量分析。结果所制摇头丸的主要成分为丙二醛。第二丰富的成分是mdm,而MDMA的纯度最低。所有的石碑形状都像“星球大战冲锋队的头”,颜色为米白色。片剂质量为0.32 ~ 0.36 g。每片精神活性物质的含量范围为:MDA 38 ~ 74 mg, MDMA 12 ~ 28 mg, MDMA 3 ~ 9 mg。结论近三年来,摇头丸中引入了新成分MDDM。MDDM产生轻微的精神作用,但没有很好地表征。它是一种新型精神活性物质,关于其药理特性、代谢、毒性和用量的资料很少。由于MDDM、MDA和MDMA之间可能存在相互作用,服用含有此类混合物的片剂可能导致意外过量和危险的协同效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Emerging trends in drugs, addictions, and health
Emerging trends in drugs, addictions, and health Pharmacology, Psychiatry and Mental Health, Forensic Medicine, Drug Discovery, Pharmacology, Toxicology and Pharmaceutics (General)
CiteScore
2.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信